Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by André Pèlegrin
Last modified by standudu
Group name EquipeAP
Item Type Journal Article
Title Examination of HER3 targeting in cancer using monoclonal antibodies
Creator Gaborit et al.
Author Nadège Gaborit
Author Ali Abdul-Hai
Author Maicol Mancini
Author Moshit Lindzen
Author Sara Lavi
Author Orith Leitner
Author Lucile Mounier
Author Myriam Chentouf
Author Sai Dunoyer
Author Manjusha Ghosh
Author Christel Larbouret
Author Thierry Chardès
Author Hervé Bazin
Author André Pèlegrin
Author Michael Sela
Author Yosef Yarden
Abstract The human EGF receptor (HER/EGFR) family of receptor tyrosine kinases serves as a key target for cancer therapy. Specifically, EGFR and HER2 have been repeatedly targeted because of their genetic aberrations in tumors. The therapeutic potential of targeting HER3 has long been underestimated, due to relatively low expression in tumors and impaired kinase activity. Nevertheless, in addition to serving as a dimerization partner of EGFR and HER2, HER3 acts as a key player in tumor cells' ability to acquire resistance to cancer drugs. In this study, we generated several monoclonal antibodies to HER3. Comparisons of their ability to degrade HER3, decrease downstream signaling, and inhibit growth of cultured cells, as well as recruit immune effector cells, selected an antibody that later emerged as the most potent inhibitor of pancreatic cancer cells grown as tumors in animals. Our data predict that anti-HER3 antibodies able to intercept autocrine and stroma-tumor interactions might strongly inhibit tumor growth, in analogy to the mechanism of action of anti-EGFR antibodies routinely used now to treat colorectal cancer patients.
Publication Proceedings of the National Academy of Sciences of the United States of America
Volume 112
Issue 3
Pages 839-844
Date Jan 20, 2015
Journal Abbr Proc. Natl. Acad. Sci. U.S.A.
Language eng
DOI 10.1073/pnas.1423645112
ISSN 1091-6490
Library Catalog NCBI PubMed
Extra 00000 PMID: 25564668
Tags collaboration, original
Date Added 2019/12/12 - 17:39:20
Date Modified 2020/01/09 - 18:10:20
Notes and Attachments PNAS_Gaborit_N_2014.pdf (Attachment)
PubMed entry (Attachment)


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés